- Home
- ILMN vs DXCM Comparison
ILMN vs DXCM Comparison
Compare ILMN & DXCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ILMN
- DXCM
- Stock Information
- Founded
- ILMN 1998
- DXCM 1999
- Country
- ILMN United States
- DXCM United States
- Employees
- ILMN N/A
- DXCM N/A
- Industry
- ILMN Medical Specialities
- DXCM Medical/Dental Instruments
- Sector
- ILMN Health Care
- DXCM Health Care
- Exchange
- ILMN Nasdaq
- DXCM Nasdaq
- Market Cap
- ILMN 23.6B
- DXCM 28.0B
- IPO Year
- ILMN 2000
- DXCM 2005
- Fundamental
- Price
- ILMN $146.43
- DXCM $78.93
- Analyst Decision
- ILMN Buy
- DXCM Buy
- Analyst Count
- ILMN 19
- DXCM 17
- Target Price
- ILMN $162.67
- DXCM $98.00
- AVG Volume (30 Days)
- ILMN 2.0M
- DXCM 3.5M
- Earning Date
- ILMN 02-06-2025
- DXCM 02-06-2025
- Dividend Yield
- ILMN N/A
- DXCM N/A
- EPS Growth
- ILMN N/A
- DXCM 83.21
- EPS
- ILMN N/A
- DXCM 1.67
- Revenue
- ILMN $4,390,000,000.00
- DXCM $3,954,000,000.00
- Revenue This Year
- ILMN N/A
- DXCM $13.10
- Revenue Next Year
- ILMN $4.28
- DXCM $14.79
- P/E Ratio
- ILMN N/A
- DXCM $47.32
- Revenue Growth
- ILMN N/A
- DXCM 16.19
- 52 Week Low
- ILMN $97.36
- DXCM $62.34
- 52 Week High
- ILMN $156.66
- DXCM $142.00
- Technical
- Relative Strength Index (RSI)
- ILMN 54.43
- DXCM 57.86
- Support Level
- ILMN $140.67
- DXCM $77.33
- Resistance Level
- ILMN $151.75
- DXCM $81.12
- Average True Range (ATR)
- ILMN 4.70
- DXCM 2.49
- MACD
- ILMN 0.70
- DXCM -0.04
- Stochastic Oscillator
- ILMN 66.11
- DXCM 65.85
About ILMN Illumina Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2023 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
About DXCM DexCom Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.